Taken together, our study also provides a rationale that HSP90 inhibitors are the possible therapeutic agents in the case of JAK2 kinase inhibitor-resistant mutations and suggests the importance of the clinical evolution of HSP90 inhibitors in drug-resistant MPN patients. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.